For Research Use Only — Not for Human Consumption
Retatrutide research peptide vial UK
>99% Purity EU Warehouse

Retatrutide

Triple GLP-1/GIP/Glucagon agonist — up to -24.2% body weight in 48 weeks (NEJM 2023)

Select Quantity

Order Now — Research Use Only →

Secure checkout via Peptide-Pay · Visa, Mastercard, Apple Pay, SEPA

Temperature: -20°C (lyophilised) / 2–8°C (reconstituted)
Conditions: Protect from light and moisture
Shelf Life: 18 months (lyophilised, sealed vial)

Research Profile

Retatrutide (LY3437943) is a novel triple-agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. Developed by Eli Lilly, it represents a paradigm shift in metabolic research by being the first molecule to address three incretin-based signalling pathways in parallel. The glucagon component fundamentally differentiates retatrutide from dual agonists: while GLP-1 and GIP synergistically enhance satiety and improve insulin sensitivity, glucagon receptor activation increases hepatic energy expenditure through elevated lipid oxidation and thermogenesis. In the randomised, double-blind Phase II study by Jastreboff et al. (NEJM 2023, n=338), participants on the highest dose achieved a mean weight reduction of -24.2% at 48 weeks — the strongest effect ever documented for a single peptide in clinical research. Supplied as lyophilised powder requiring reconstitution with bacteriostatic water before use.

Reconstitution

Solvent: Bac Water (0.9% benzyl alcohol)

Volume: 1–2 mL

Concentration: 10 mg/mL at 1 mL, 5 mg/mL at 2 mL

Key Research Findings

  • Mean weight reduction of -24.2% at 48 weeks (Jastreboff et al., NEJM 2023, n=338)
  • Triple receptor activation at GLP-1, GIP, and glucagon simultaneously
  • Hepatic steatosis reduced by up to 80% in preclinical models (Coskun et al., Cell Metabolism 2022)
  • HbA1c improvement of -1.3% and fasting glucose -18% in the highest dose cohort
  • Systolic blood pressure -7.2 mmHg and triglycerides -30% in post-hoc analysis
  • Over 90% of participants on 12 mg achieved ≥5% weight reduction at 48 weeks
  • Extended plasma half-life of ~6 days via C18 fatty acid modification — weekly dosing

Primary publication: Jastreboff et al., "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial", New England Journal of Medicine, Vol. 389, pp. 514–526 (2023), DOI: 10.1056/NEJMoa2301972. Randomised, double-blind, placebo-controlled study across 25 US centres, 338 adults, 48 weeks. Phase III TRIUMPH programme (NCT05929066) ongoing at 45+ centres worldwide.

Frequently Asked Questions

Retatrutide (LY3437943) is a triple GLP-1/GIP/glucagon receptor agonist developed by Eli Lilly, currently under Phase III evaluation. It demonstrated a mean -24.2% body weight reduction at 48 weeks in a Phase II trial (NEJM 2023).
Semaglutide activates GLP-1 only. Tirzepatide activates GLP-1 and GIP. Retatrutide additionally activates the glucagon receptor, adding hepatic lipid oxidation and thermogenesis as a third mechanism — contributing to its superior efficacy signal in Phase II.
Store lyophilised vials at -20°C. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 28 days.

Related Research Compounds

Research Peptides · EU Warehouse 10+ compounds · >99% purity
Browse